China Resources Pharmaceutical Group Limited (CHINARES PHARMA, 03320) announced that its 29.08%-owned subsidiary KPC Pharmaceuticals (KPC) recorded a sharp downturn in interim results for the six months ended 30 June 2026.

Revenue slumped 50.97% year on year to RMB 1.64 billion, compared with RMB 3.35 billion in the prior-year period. The deterioration cascaded to the bottom line: KPC swung to a net loss attributable to shareholders of RMB 0.36 billion, versus a profit of RMB 0.20 billion a year earlier. Excluding extraordinary items, the loss widened to RMB 0.39 billion.

Operating cash flow reversed to an outflow of RMB 0.51 billion from an inflow of RMB 0.22 billion in the first half of 2025, underlining pressure on liquidity. Basic and diluted earnings per share both declined to a loss of RMB 0.48, compared with earnings of RMB 0.26 in the previous corresponding period.

Balance-sheet metrics also weakened. Total assets contracted 6.74% to RMB 10.98 billion from RMB 11.77 billion at end-2025, while net assets attributable to shareholders fell 9.29% to RMB 4.86 billion. The weighted average return on net assets moved to –7.03%, down 10.73 percentage points year on year.

KPC’s unaudited interim figures were prepared under PRC GAAP and remain subject to audit adjustments. The disclosure covers only KPC and does not constitute a full representation of CHINARES PHARMA’s consolidated performance. Shareholders and investors are advised to exercise caution when dealing in the company’s securities.